CA
GPCR icon

CoreCap Advisors’s Structure Therapeutics GPCR Stock Holding History

CoreCap Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77
Closed -$1.33K – 2948
2025
Q1 		$1.33K Hold
77
– – ﹤0.01% 2463
2024
Q4 		$2.09K Buy
+77
New +$2.73K ﹤0.01% 2219

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CoreCap Advisors's GPCR Position: Q2 2025 in Review

CoreCap Advisors sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 77 shares — an estimated $1.33K sold.

CoreCap Advisors first reported a position in GPCR in Q4 2024 and held it in 2 quarters. The position peaked at $2.09K in Q4 2024. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

  • CoreCap Advisors reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 77 Structure Therapeutics shares in Q2 2025, an estimated $1.33K.
  • CoreCap Advisors first reported a position in Structure Therapeutics in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Structure Therapeutics position peaked at $2.09K in Q4 2024.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.